Alnylam Pharmaceuticals, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report; quarterly results are not clearly provided in the supplied text.
Business context
Alnylam is a commercial-stage biopharmaceutical company developing RNA interference (RNAi) medicines. It reported four products generating its own product sales—ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO—and a fifth approved product, Leqvio, developed and commercialized by Novartis. Its pipeline spans genetic, cardiometabolic, hepatic infectious, and CNS/ocular diseases.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenue | $1.037 billion | $844.3 million | Up 23% |
| Net product revenue | $894.3 million | $662.1 million | Up 35% |
| Collaboration revenue | $134.9 million | $181.0 million | Down 25% |
| Royalty revenue | $8.2 million | $1.2 million | Up $7.0 million |
| Operating costs and expenses | $1.822 billion | $1.553 billion | Up 17% |
| Loss from operations | $(785.1) million | $(708.7) million | Loss widened |
| Net loss | $(1.131) billion | $(852.8) million | Loss widened 33% |
| Net cash used in operations | $(541.3) million | $(641.7) million | Cash use decreased |
- Product sales: ONPATTRO $557.6 million; AMVUTTRA $93.8 million following its 2022 launch; GIVLAARI $173.1 million; OXLUMO $69.8 million. Management attributed sales growth to more patients on treatment and AMVUTTRA’s launch.
- Margins: Cost of goods sold was 15.7% of product revenue, implying an approximately 84.3% product gross margin before other operating costs. The filing does not provide a consolidated gross-margin figure. R&D was $883.0 million and SG&A was $770.7 million.
- Cash and liquidity: Cash, cash equivalents and marketable securities totaled $2.19 billion at year-end, versus $2.44 billion in 2021. Current assets were $2.692 billion and current liabilities $767.9 million. Management stated available resources and expected receipts should fund operations for at least 12 months from the filing date.
- Debt and obligations: Alnylam issued $1.035 billion principal amount of 1.00% convertible notes due 2027; year-end carrying value was $1.017 billion. It used proceeds to repay the Blackstone term loan, including $700 million principal and $62.1 million prepayment premiums. The company also recorded a $1.292 billion liability for sold future Leqvio royalties, including $40.3 million current.
- Other financial items: Total other expense was $341.9 million, including a $76.6 million loss on extinguishment of debt, $33.3 million of marketable-equity-security losses, and a $94.7 million unfavorable fair-value change in the development derivative liability. Interest expense was $156.0 million.
Material changes and developments
- Revenue growth was led by product sales, while collaboration revenue declined, mainly because of lower reimbursable research and manufacturing activity and timing of work.
- Operating expenses increased, particularly SG&A, reflecting AMVUTTRA’s launch and broader commercial, staffing and infrastructure investments. R&D spending also rose, including work on zilebesiran Phase 2 studies.
- Operating cash use improved year over year, but net loss widened, partly due to higher other expense and the debt extinguishment charge.
- AMVUTTRA received U.S. approval in June 2022 and approvals in additional markets. OXLUMO’s U.S. label was expanded to include lowering plasma as well as urinary oxalate in pediatric and adult patients.
Outlook, commentary and risks
- Management expected 2023 product revenue to increase as patient numbers grow and products enter additional markets, subject to regulatory approvals. It also expected R&D and SG&A expenses to rise. The supplied filing text does not provide clear numerical 2023 guidance.
- Alnylam’s P5x25 objectives include six or more marketed products, more than 20 clinical programs, revenue CAGR of at least 40% through year-end 2025, and sustainable non-GAAP profitability during the period. These are targets, not assured outcomes.
- The FDA accepted ONPATTRO’s supplemental application for ATTR cardiomyopathy; the stated action date was October 8, 2023, with an advisory committee meeting planned. APOLLO-B met its primary endpoint, with a 14.7-meter median difference in six-minute walk test versus placebo (p=0.0162); a composite endpoint result was not statistically significant (p=0.0574).
- HELIOS-B topline results were expected in early 2024. KARDIA-1 zilebesiran Phase 2 results were anticipated in mid-2023 and KARDIA-2 results around year-end 2023. Fitusiran filing timing had moved to 2024 following safety-related protocol changes.
- Management cited continuing loss history and dependence on successful commercialization, clinical development, reimbursement, partnerships and manufacturing. COVID-19, geopolitical disruption, foreign-exchange movements, competition, pricing reform and reliance on third-party manufacturers and collaborators were also identified risks.
- The DOJ investigation into ONPATTRO marketing and promotion remained ongoing; the company was cooperating, and it said no loss was determined probable or reasonably estimable. Alnylam’s patent-infringement cases against Pfizer/BioNTech and Moderna sought damages; trials were scheduled for November 2024.
- Regeneron opted out of the cemdisiran monotherapy collaboration in November 2022, leaving Alnylam responsible for further development and commercialization costs. Separately, Alnylam discontinued plans for a Phase 3 vutrisiran Stargardt disease study, citing evaluation of the Inflation Reduction Act’s impact.
Most important facts for investors to verify
- Whether product-sales growth, especially AMVUTTRA adoption, is sustained and translates into improving operating performance and cash generation.
- Actual 2023 revenue and expense guidance, and progress toward P5x25 revenue-growth and profitability targets.
- ONPATTRO’s cardiomyopathy review outcome and HELIOS-B results, including the competitive and reimbursement implications.
- The assumptions behind Leqvio-related royalty forecasts and the $1.292 billion royalty-sale liability; this estimate was identified by the auditor as a critical audit matter.
- Developments in the DOJ investigation, patent litigation, and fitusiran’s safety and regulatory timeline.
- Availability of the $2.19 billion year-end liquidity figure, including the distinction between cash and cash equivalents and marketable securities, and the company’s future financing and debt-servicing needs.